Multiple Myeloma Clinical Trials in Louisville, Kentucky

8 studies are recruiting for multiple myeloma in Louisville, Kentucky right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

2. Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

   Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy.

   Stage

   Not phased

   Ages

   10 and older

   Site

   Norton Healthcare Cancer Center, Louisville, Kentucky

   Locations

   6 in total

   Run by

   Leuko Labs, Inc.

   See if you can join NCT06323447 on ClinicalTrials.gov

3. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   157 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07258511 on ClinicalTrials.gov

4. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

   The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   40 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT03761108 on ClinicalTrials.gov

5. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Norton Women's and Children's Hospital, Louisville, Kentucky

   Locations

   52 in total

   Run by

   Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

   See if you can join NCT06297226 on ClinicalTrials.gov

6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   173 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

7. Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

   This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Healthcare, Inc., Louisville, Kentucky

   Locations

   24 in total

   Run by

   Heidelberg Pharma AG

   See if you can join NCT04879043 on ClinicalTrials.gov

8. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

   This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Norton Cancer Institute, Louisville, Kentucky

   Locations

   32 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05828511 on ClinicalTrials.gov